Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 4 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Revolution Medicines Inc. currently manages 10 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 9 distinct examiners, suggesting a broad spread of oversight for the pending matters. The work is concentrated within 4 distinct art units, which indicates a focused technical scope despite the number of individual examiners involved. This concentration suggests that while multiple examiners are active, they are likely operating within similar procedural frameworks and technical guidelines established by those 4 specific art units.
Examiner CHANDRAKUMAR, NIZAL S is the busiest individual assigned to this portfolio, currently handling 2 pending office actions. This represents a small portion of the 10 total pending actions, reflecting a decentralized prosecution strategy where no single examiner holds a dominant share of the work. Practitioners should note that the presence of 9 distinct examiners for only 10 pending actions means that almost every matter is being reviewed by a unique set of eyes. This diversity of examiners, paired with the focus in 4 art units, requires a prosecution approach that balances individual examiner preferences with the broader trends of the assigned technical groups.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (40%) |
| §112 only | 2 (20%) |
| Double-patenting only | 1 (10%) |
| Multi-statute (no §101) | 3 (30%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 2 | 72.7% | +18.3% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| SANCHEZ, JUSTIN CHRISTOPHER | 1 | 88.7% | +10.2% |
| KIM, SEONG JONG | 1 | 25.0% | +0.0% |
| CHAO, ALLEN | 1 | 55.6% | +0.0% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| MCDOWELL, BRIAN E | 1 | 74.1% | +30.8% |
| BAUER, NICOLA MARIA | 1 | 58.3% | +50.0% |
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634289 | CRYSTALLINE FORMS OF RAS INHIBITORS, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USE THEREOF | INAM, SAHAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18771135 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | SANCHEZ, JUSTIN CHRISTOPHER | — |
| 18769009 | RAS INHIBITORS | KIM, SEONG JONG | — |
| 18559932 | USE OF SOS1 INHIBITORS WITH MTOR INHIBITORS TO TREAT CANCERS | BAUER, NICOLA MARIA | — |
| 18479500 | METHODS FOR INHIBITING RAS | LADD, CAROLYN LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18011454 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | CHANDRAKUMAR, NIZAL S | 132d overdue |
| 19308717 | RAS INHIBITORS | RZECZYCKI, PHILLIP MATTHEW | — |
| 18795852 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | CHANDRAKUMAR, NIZAL S | — |
| 18771135 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | SANCHEZ, JUSTIN CHRISTOPHER | — |
| 18591721 | RAS INHIBITORS | MCDOWELL, BRIAN E | — |
| 18559932 | USE OF SOS1 INHIBITORS WITH MTOR INHIBITORS TO TREAT CANCERS | BAUER, NICOLA MARIA | — |
| 18479500 | METHODS FOR INHIBITING RAS | LADD, CAROLYN LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1622 | 3 |
| 1625 | 2 |
| 1624 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19308717 | RAS INHIBITORS | RZECZYCKI, PHILLIP MATTHEW | 1625 | DP | Non-Final OA | — | Pending | Aug 25, 2025 |
| 18795852 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | CHANDRAKUMAR, NIZAL S | — | §103Other | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18771135 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | SANCHEZ, JUSTIN CHRISTOPHER | — | §102§112Other | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18769009 | RAS INHIBITORS | KIM, SEONG JONG | — | §112 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18634246 | SYNTHESIS OF RAS INHIBITORS | CHAO, ALLEN | 1622 | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18634289 | CRYSTALLINE FORMS OF RAS INHIBITORS, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USE THEREOF | INAM, SAHAR | 1622 | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18591721 | RAS INHIBITORS | MCDOWELL, BRIAN E | 1624 | §112Other | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18559932 | USE OF SOS1 INHIBITORS WITH MTOR INHIBITORS TO TREAT CANCERS | BAUER, NICOLA MARIA | 1621 | §103§112 | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18479500 | METHODS FOR INHIBITING RAS | LADD, CAROLYN LOUISE | 1622 | §102§112 | Non-Final OA | — | Pending | Oct 02, 2023 |
| 18011454 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | CHANDRAKUMAR, NIZAL S | 1625 | §103 | Final Rejection | 132d overdue | Pending | Dec 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial